Online inquiry

IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8884MR)

This product GTTS-WQ8884MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets IFNA1; IFNB1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3; NM_002176.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439; 3456
UniProt ID P01562; P01574
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8884MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4617MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ15765MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ10918MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ7331MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ4693MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ4316MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ13295MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ1857MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AG1-25
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW